Case closed: Neutrons settle 40-year debate on enzyme for drug design
Filter News
Area of Research
- (-) Nuclear Science and Technology (3)
- Advanced Manufacturing (1)
- Biology and Environment (19)
- Clean Energy (15)
- Computational Engineering (1)
- Computer Science (1)
- Fusion and Fission (4)
- Isotopes (5)
- Materials (38)
- Materials for Computing (3)
- National Security (14)
- Neutron Science (14)
- Sensors and Controls (1)
- Supercomputing (23)
News Topics
- (-) Biomedical (1)
- (-) Physics (2)
- 3-D Printing/Advanced Manufacturing (2)
- Advanced Reactors (3)
- Bioenergy (1)
- Computer Science (1)
- Decarbonization (1)
- Fusion (2)
- Isotopes (2)
- Materials Science (1)
- Neutron Science (1)
- Nuclear Energy (10)
- Space Exploration (2)
- Sustainable Energy (1)
- Transformational Challenge Reactor (1)
Media Contacts
As a teenager, Kat Royston had a lot of questions. Then an advanced-placement class in physics convinced her all the answers were out there.
The Department of Energy’s Oak Ridge National Laboratory is now producing actinium-227 (Ac-227) to meet projected demand for a highly effective cancer drug through a 10-year contract between the U.S. DOE Isotope Program and Bayer.
After more than a year of operation at the Department of Energy’s (DOE’s) Oak Ridge National Laboratory (ORNL), the COHERENT experiment, using the world’s smallest neutrino detector, has found a big fingerprint of the elusive, electrically neutral particles that interact only weakly with matter.